EP Patent

EP0160501A2 — Sustained release intranasal formulation and method of use thereof

Assigned to Eli Lilly and Co · Expires 1985-11-06 · 41y expired

What this patent protects

Administration of a catecholamine by a novel intranasal delivery system provides prolonged blood levels of the drug.

USPTO Abstract

Administration of a catecholamine by a novel intranasal delivery system provides prolonged blood levels of the drug.

Drugs covered by this patent

Patent Metadata

Patent number
EP0160501A2
Jurisdiction
EP
Classification
—
Expires
1985-11-06
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.